Coronary calcium screening a low cost predictor of heart attack

Published On 2018-11-12 14:55 GMT   |   Update On 2018-11-12 14:55 GMT

Testing a patient's coronary calcium levels is a better predictor of blocked coronary arteries at risk for a heart attack, according to a new study.


Findings of the study, presented at the American Heart Association Scientific Session 2018 in Chicago, demonstrates that it can also assess the need for revascularization better than standard risk-assessment equations used in medical practice today.


"With coronary calcium, we're looking at a marker indicating the actual presence of anatomic disease -- we're not just looking at probabilities of disease based on a patient's standard risk factors," said Jeffrey L. Anderson, a cardiologist and cardiovascular researcher at the Intermountain Medical Center Heart Institute in Salt Lake City. "The risk factors are worth knowing, but they don't tell whether or not you actually have the disease."


Also Read: High dietary calcium in men associated with increased mortality

In the new study, the researchers identified 1,107 symptomatic patients who presented to the healthcare system without any known coronary artery disease and who had a PET-stress test to measure coronary flow, conducted as part of their diagnostic evaluation.


The PET/CT test also enabled a coronary calcium score to be measured. Based on the coronary calcium score and standard risk factors documented in their medical records, three different atherosclerotic cardiovascular disease risk scores were calculated: the standard Pooled Cohort Equation (based on traditional risk factors), the Multi-Ethnic Study of Atherosclerosis (MESA) Risk Score (which combines coronary calcium and traditional risk factors), and the Coronary Calcium Score alone


Researchers tracked those patients to identify who, based on PET scan results suggesting a blocked artery, went on to revascularization (a coronary stent or bypass surgery) and who had a subsequent heart attack or died during the subsequent two years.


Also Read: Short acting Calcium channel blockers linked to pancreatic cancer

Key Findings:

  • Risk equations that included coronary artery calcium measurements, i.e., the MESA Score and the Coronary Calcium Risk Score, were better able to predict the presence of symptomatic coronary artery disease requiring revascularization than the Pooled Cohort Equation, which relies only on standard risk factors such as age, gender, blood pressure, and cholesterol measurements.

  • After the PET-scan results were acted upon, all three equations were only moderately successful in determining who over two years of follow-up would go on to die or have a heart attack.

  • Of the 29 patients who showed no coronary artery calcium, none had any major heart problems in the time-period tracked.


"Calcium in the artery doesn't tell you the extent of soft plaque, but it does mark that disease is present," Dr. Anderson said. "These results tell us that coronary calcium adds importantly to probability estimates."


He also said the cost of coronary calcium screening is low, in the range of $100 or less, and should be considered in the future as part of routine medical care after age 50 for men and 55-60 for women.


"We accept that mammograms should be done for women and colonoscopies should be done for everybody at a certain age, and they're much more expensive than a calcium scan," he said.


Dr. Anderson hopes the findings lead to coronary calcium tests becoming more accepted and covered by medical insurance as a means to better predict who is at coronary risk, which not only will get high-risk patients into treatment earlier but also keeps patients who aren't truly at risk from being overtreated.

Article Source : With inputs from AHA Scientific Session 2018

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News